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Aims Atrial fibrillation (AF) often starts as a paroxysmal self-terminating arrhythmia. Limited information is available on
AF patterns and episode duration of paroxysmal AF. In paroxysmal AF patients, we longitudinally studied the tem-




In this interim analysis of the Reappraisal of AF: Interaction Between HyperCoagulability, Electrical Remodelling,
and Vascular Destabilisation in the Progression of AF (RACE V) registry, 202 patients with paroxysmal AF were fol-
lowed with continuous rhythm monitoring (implantable loop recorder or pacemaker) for 6 months. Mean age was
64 ± 9 years, 42% were women. Atrial fibrillation history was 2.1 (0.5–4.4) years, CHA2DS2-VASc 1.9 ± 1.3, 101
(50%) had hypertension, 69 (34%) heart failure. One-third had no AF during follow-up. Patients with long episodes
(>12 hours) were often men with more comorbidities (heart failure, coronary artery disease, higher left ventricular
mass). Patients with higher AF burden (>2.5%) were older with more comorbidities (worse renal function, higher
calcium score, thicker intima media thickness). In 179 (89%) patients, 1-year rhythm follow-up was available. On a
quarterly basis, average daily AF burden increased from 3.2% to 3.8%, 5.2%, and 6.1%. Compared to the first 6
months, 111 (62%) patients remained stable during the second 6 months, 39 (22%) showed progression to longer
AF episodes, 8 (3%) developed persistent AF, and 29 (16%) patients showed AF regression.
...................................................................................................................................................................................................
Conclusions In paroxysmal AF, temporal patterns differ suggesting that paroxysmal AF is not one entity. Atrial fibrillation burden
is low and determined by number of comorbidities. Atrial fibrillation progression occurred in a substantial number.
...................................................................................................................................................................................................
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Introduction
Traditionally, atrial fibrillation (AF) is clinically categorized into parox-
ysmal, persistent, long-standing persistent, and permanent AF.1 Often
starting as short-lasting, paroxysmal episodes, AF commonly pro-
gresses over time to persistent and permanent, non-selfterminating
AF.2 Progression of AF is associated with a higher incidence of major
adverse cardiovascular and cerebrovascular events.3,4 However,
most data on AF and AF progression is obtained with intermittent
rhythm monitoring, providing limited information on the total burden
and the temporal pattern of AF.1,5,6 In the era of implantable loop
recorders, it is now possible to assess progression of AF more pre-
cisely.7 These devices also provide information on the exact temporal
AF pattern and number and duration of AF episodes, which may help
explaining differences in underlying pathophysiological AF mecha-
nisms and related clinical outcomes. Ultimately, this could aid to per-
sonalize AF therapy and may have clinical utility for the assessment of
AF treatment response.
Recently, the first initiatives for an improved classification for par-
oxysmal AF have been proposed, based on single-lead electrocardio-
gram (ECG) monitoring.8 The Reappraisal of Atrial Fibrillation:
Interaction Between HyperCoagulability, Electrical Remodelling, and
Vascular Destabilisation in the Progression of Atrial Fibrillation
(RACE V) registry aims to elucidate the factors associated with AF
progression. At baseline, deep phenotyping of patients with paroxys-
mal self-terminating AF is performed. Exact longitudinal assessment
of episode number and duration and AF burden is provided by con-
tinuous rhythm monitoring through an implantable loop recorder or
pacemaker with the same AF detection algorithm. In the present
interim analysis, we aim to longitudinally study AF temporal patterns,
burden and short-term progression of AF and their association with
clinical characteristics, in patients with paroxysmal self-terminating
AF using continuous rhythm monitoring.
Methods
Patient population
The RACE V is an investigator-initiated, prospective, multicentre registry
aiming to include 750 patients in multiple centres in The Netherlands.
A total of 202 patients were included in five centres for the current in-
terim analysis between June 2016 and December 2017. Inclusion criteria
included patients aged >18 years with paroxysmal AF; a maximum history
of 10 years since diagnosis at the moment of inclusion; a maximum
CHA2DS2-VASc score of 5; and no other indication for anticoagulation
drugs (e.g. mechanical valve prosthesis). Patients had to have at least two
documented episodes of paroxysmal AF in the past year or one docu-
mented episode combined with at least two symptomatic episodes in the
past year suspected to be AF. In patients with a Medtronic AdvisaVR pace-
maker, atrial high rate episodes (AHRE) >190 beats per minute lasting
>6 min were qualified as AF episodes. Patients with other types of pace-
makers, defibrillators, or cardiac resynchronization therapy could not
participate due to differences in AHRE algorithm or incompatibility with
the type of home-monitoring. Patients with a history of persistent AF,
currently treated with amiodarone, current pregnancy, or a life expec-
tancy <2.5 years were not eligible to participate. Patients with AF caused
exclusively by transient triggers (e.g. post-operative, due to infection)
could also not participate, as well as patients with a previous pulmonary
vein isolation (PVI), or intention to undergo PVI. The study was per-
formed in concordance with the Declaration of Helsinki. The Institutional
Review Board approved the protocol, and the study was registered at
Clinicaltrials.gov (identifier NCT02726698). All centres approved the
protocol and all patients gave written informed consent. Intended total
follow-up duration is 2.5 years.
Study procedures
All patients received causal therapy for AF, as well as rate and rhythm
control according to the European Society of Cardiology AF guidelines.
At baseline, information on clinical characteristics, medical history, AF
characteristics, symptomatology, and current medication were collected.
Additionally, all patients underwent physical examination, a 12-lead ECG,
echocardiography, cardiac computed tomography (CT), vascular assess-
ment, and blood sampling. Quality of life, AF-related symptoms, and phys-
ical activity were assessed through questionnaires. After baseline,
additional follow-up visits were planned at 1 and 2.5 years.
The cardiac CT was performed as a non-contrast ECG-gated scan
with slice collimation of 0.6 mm and a tube voltage of 120 kV. Beta-
blockers were administered in case of high heart rates to improve image
quality. Cranial demarcation was placed at the aortic arch or higher and
What’s new?
• We assessed temporal patterns of paroxysmal selfterminating
atrial fibrillation (AF) by continuous rhythm monitoring in
patients receiving a loop recorder for study purposes.
Temporal AF patterns showed to be heterogeneous in terms
of duration of AF episodes as well as AF burden.
• Patients with longer episodes of paroxysmal AF had more un-
derlying conditions.
• Using continuous rhythm monitoring, AF progression within 1-
year occurred in a substantial number of patients.
• Continuous rhythm monitoring enables an improved charac-
terization of patients with AF. Diverse patterns may reflect dif-
ferences in underlying diseases and mechanisms, warranting
personalized therapeutic interventions and patient-tailored
therapies.
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caudal demarcation was placed to include the whole heart. Automated
coronary calcium scores (Agatston) were collected.
Vascular assessment included pulse wave velocity (PWV) and intima
media thickness (IMT) measurements. Pulse wave velocity was measured
by SphygmoCor (Atcor Medical Blood Pressure Analysis System,
Australia) or Complior (Alam Medical, France) at the carotid and femoral
arteries. To determine aortic PWV, >_20 consecutive pressure wave-
forms were collected at the carotid artery and the femoral artery. The
system software calculated the wave transit time, using the R wave of the
simultaneously recorded ECG. Distance between both measure points
was determined and corrected by multiplying the distance by 0.8. The
PWV was calculated by dividing the corrected distance by the wave tran-
sit time. Intima media thickness measurements were performed by ultra-
sound (Siemens Acuson S2000) with the Syncho US Workplace 3.5,
Arterial Health Package for automated IMT measurement. Intima media
thickness was bilaterally assessed in the common carotid artery, the ca-
rotid bifurcation, and internal carotid artery.
Rhythm follow-up
All patients had continuous rhythm monitoring to detect the exact AF
burden (time spent in AF) and temporal AF pattern (the number and du-
ration of AF episodes). Patients either received a Medtronic Reveal
LINQVR implantable loop recorder subcutaneously merely for study pur-
poses, or had a Medtronic AdvisaVR pacemaker implanted prior to inclu-
sion. All patients received a home monitoring device (Medtronic
CarelinkVR ) in order to receive all data regarding cardiac arrhythmias on
the Carelink NetworkVR . Patients were instructed to perform at least
weekly manual data transmissions to prevent potential data loss. AT/AF
detection setting was set to AF detection only. Additional settings in-
cluded a tachy-pause-brady data storage priority and balanced sensitivity
for AF detection with nominal ectopy rejection for all patients. All epi-
sodes of AF >_2 min were automatically detected. Episodes >_182 beats
per minute with a duration of >_24 beats were automatically classified as
tachycardia and if applicable, corrected to AF episodes. First, a dedicated
service (Fysiologic, Amsterdam, The Netherlands) adjudicated all epi-
sodes. As a second assessment all episodes were independently adjudi-
cated by two physicians (R.R.D.W.; Ö.E.) and corrected if needed.
Information on changes in antiarrhythmic drug (AAD) therapy, electrical
cardioversions (ECV) and PVI were collected during follow-up.
Atrial fibrillation patterns
Atrial fibrillation patterns during 6 months (183 days) were visualized by
custom-made software using Microsoft Visual Basic. First day of monitor-
ing started at mid-night the day after loop recorder implantation or at
mid-night the day after inclusion in patients with a pacemaker. Atrial fibril-
lation patterns were independently adjudicated by four physicians
(R.R.D.W.; Ö.E.; H.J.G.M.C.; I.C.V.G.), At first, all patients were divided
into having no recurrence of AF or >_1 episode of AF during follow-up.
Secondly, patients with AF episodes were divided by into short AF epi-
sodes duration (<6 hours), intermediate (6–12 hours), and long AF epi-
sodes (>12 hours) by their longest AF episode during the first 6 months.
Third, AF burden was calculated by the cumulative time in AF divided by
the total follow-up time, expressed as a percentage. In addition, patients
were divided according to degree of AF burden: low AF burden (>0–
0.5%), intermediate (>0.5–.5%), and high AF burden (>2.5%). The afore-
mentioned cut-offs for AF burden were used to create equally sized
groups.
Atrial fibrillation progression was assessed in 179 patients in whom
1 year (366 days) of rhythm follow-up was available. These patients were
also divided into no AF, short, intermediate, and long episodes according
to the second 6 months of rhythm follow-up. Progression of AF was
defined as deterioration of episode duration category (e.g. short to inter-
mediate episodes) in the second 6 months, compared to the first
6 months. Regression was defined as episode category improvement (e.g.
intermediate to short episodes). Daily averaged AF burden was calculated
by the sum of the daily AF burden from all patients and divided by the
number of patients. Patients with episodes >7 days were considered to
have persistent AF.
Covariate definition
Covariate definitions that were used are shown in the Supplementary ma-
terial online.
Statistical analysis
Data were presented as means ± standard deviation or median with
interquartile range, depending on normality of the data. Categorical data
were presented as numbers with percentages. Differences between
patients with and without AF recurrence were tested by Student’s t-test,
Mann–Whitney U test or Fisher’s exact (2 categories) or v2 (>2 catego-
ries). Differences between different AF patterns were analysed by
one-way ANOVA in normally distributed data, Kruskall–Wallis test in
non-normally distributed data or v2 in categorical data. Additional sensi-
tivity analyses were performed excluding the following groups: (i) patients
that underwent PVI or ECV during follow-up; (ii) patients that underwent
PVI, ECV, or had changes in AAD therapy during follow-up; and (iii)
patients that underwent PVI, ECV, or any AAD therapy during follow-up.
Spearman’s correlation coefficient, including 95% confidence interval
(CI), was calculated to assess the relation of AF burden and the duration
of the longest AF episode. Changes in the duration of longest AF episode
category in the first 6 months and second 6 months were visualised using
a Sankey diagram. All analyses were performed by IBM SPSS Statistics for
Windows version 23.0 (Armonk, New York, USA) and GraphPad Prism




Baseline characteristics are shown in Table 1. Mean age was
64 ± 9 years, 85 (42%) were women, and median history of AF at
baseline was 2.1 (0.5-4.4) years. The majority had an implantable loop
recorder [185 (92%)]; 17 (8%) had a pacemaker. Patients with a pace-
maker were older (72 ± 9 vs. 64 ± 9 years, P < 0.001) and had more
comorbidities (2.9 ± 1.5 vs. 2.3 ± 1.3, P = 0.049).
Atrial fibrillation episodes
A total of 13 657 episodes of AF in 202 patients were automatically
detected by the implanted device during follow-up of 183 days, of
which 2231 (16%) episodes were adjudicated as false positive for AF,
for example due to premature atrial beats, ventricular extra beats or
artefacts. Most (93%) false positive episodes lasted <_10 min. Forty
episodes of AF were originally classified as tachycardia. After applying
all corrections, 11 466 episodes of AF remained, with a median AF
burden of 0.3% (0–2.1%, maximal burden 61.1%) during 6-months
follow-up (total of 36 966 days of continuous day-to-day heart
rhythm data for analysis). Of these 11 466 episodes, 11 456 (>99.9%)
episodes were self-terminating. Ten episodes in eight patients were
non-selfterminating AF. These patients underwent an ECV. Of these
eight patients, two had short, three had intermediate, and three had
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of AF (N 5 63)
Recurrence
of AF (N 5 139)
P-value (no recurrence
vs. recurrence)
Age (years) 64 ± 9 64 ± 10 64 ± 9 0.900
Male sex 117 (58%) 36 (57%) 81 (58%) 0.880
Total history AF (years) 2.1 (0.5–4.4) 1.9 (0.5–5.3) 2.2 (0.6–4.5) 0.574
Heart failure 69 (34%) 21 (33%) 48 (35%) 0.868
Hypertension 101 (50%) 40 (64%) 61 (44%) 0.010
Diabetes mellitus 19 (9%) 8 (13%) 11 (8%) 0.304
Coronary artery disease 23 (11%) 5 (8%) 18 (13%) 0.299
Thrombo-embolic events 22 (11%) 9 (14%) 13 (9%) 0.297
Chronic obstructive pulmonary disease 11 (5%) 3 (5%) 8 (6%) 0.773
Number of comorbiditiesa 2.3 ± 1.3 2.5 ± 1.3 2.3 ± 1.3 0.199
CHA2DS2-VASc score
b 1.9 ± 1.3 2.2 ± 1.3 1.8 ± 1.3 0.030
0 25 (12%) 4 (6%) 21 (15%)
1 56 (28%) 14 (22%) 42 (30%)
2 60 (30%) 25 (39%) 35 (25%)
3 35 (17%) 8 (12%) 27 (19%)
4 18 (9%) 7 (11%) 11 (8%)
5 8 (4%) 5 (8%) 3 (2%)
EHRA class 0.143
I 22 (11%) 9 (14%) 13 (9%)
IIa 84 (42%) 24 (38%) 60 (43%)
IIb 78 (39%) 28 (44%) 50 (36%)
III 18 (9%) 2 (3%) 16 (12%)
Height (cm) 176 ± 10 176 ± 10 176 ± 11 0.873
Weight (kg) 86 ± 17 85 ± 15 86 ± 18 0.747
BMI (kg/m2) 28 ± 5 28 ± 5 28 ± 5 0.956
Obesity (BMI > 30) 50 (25%) 17 (27%) 33 (24%) 0.621
Waist circumference (cm) 102 ± 13 103 ± 14 102 ± 13 0.692
Blood pressure (mmHg)
Systolic 136 ± 18 135 ± 17 137 ± 19 0.458
Diastolic 81 ± 10 80 ± 11 81 ± 9 0.649
NT-proBNP (pg/mL) 50 (22–144) 54 (27–123) 48 (19–159) 0.540
Creatinine (mmol/L) 82 (70–92) 82 (70–92) 82 (71–92) 0.476
eGFR (mL/min) 80 (68–88) 82 (68–91) 79 (68–88) 0.491
Medications
b-Blocker 104 (52%) 33 (52%) 71 (51%)) 0.864
Verapamil/diltiazem 31 (15%) 9 (14%) 22 (16%) 0.778
Class I antiarrhythmic drugs 41 (20%) 6 (10%) 35 (25%) 0.013
Class III antiarrhythmic drugs 11 (5%) 3 (5%) 8 (6%) 1.000
Digoxin 2 (1%) – 2 (1.4%) 0.339
ACE-inhibitor 43 (21%) 18 (29%) 25 (18%) 0.089
Angiotensin receptor blocker 44 (22%) 22 (35%) 22 (16%) 0.002
Mineralocorticoid receptor antagonist 3 (2%) – 3 (2%) 0.240
Statin 80 (40%) 27 (43%) 53 (38%) 0.524
Diuretic 33 (16%) 17 (26%) 16 (12%) 0.006
Anticoagulant 0.079
Vitamin K antagonist 33 (16%) 11 (17%) 22 (16%)
NOAC 114 (56%) 40 (63%) 74 (53%)
Echocardiographic variables
Left atrial volume (mL) 69 ± 23 62 ± 20 72 ± 24 0.013
Left atrial volume index (mL/m2) 35 ± 12 31 ± 10 37 ± 12 0.002
Left ventricular ejection fraction (%) 58 (55–60) 58 (55–60) 58 (55–60) 0.661
Continued
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long self-terminating AF episodes. Changes in AAD therapy were
made in six patients (four patients started with flecainide; one patient
started sotalol; and in one patient flecainide was stopped). Three
patients underwent a PVI within 6 months (at Days 64, 162, and 171
of follow-up, respectively), of which one patient had episodes of in-
termediate duration; and two had long episodes.
Atrial fibrillation patterns
During follow-up, 63 patients (31%) had no recurrence of AF
(Table 1). Patients without AF recurrence had more often hyperten-
sion, a higher CHA2DS2-VASc score, smaller left atria, and were
more often treated with ACE/ARB and diuretics. The estimated num-
ber of AF episodes the year before inclusion was not different from
the ones with AF recurrence [9 (2–50) vs. 10 (4–50) episodes,
P = 0.357].
Forty-five (22%) patients had short, 38 (19%) had intermediate,
and had 56 (28%) long episodes. Figure 1 shows examples of patients
with short, intermediate, and long episodes. Patients with long epi-
sodes were more often men, had more often heart failure, coronary
artery disease, a higher number of comorbidities, a larger waist cir-
cumference and higher left ventricular mass (Table 2). Several sensi-
tivity analyses were performed, excluding patients with AAD
therapy, ECV or PVI during follow-up (Supplementary material on-
line). Although not all differences remained significant, similar trends
were observed.
Fifty (25%) patients had low; 44 (22%) had intermediate; and 45
(22%) had high AF burden (Table 3). Patients with high AF burden
were older, had a higher number of comorbidities, a higher
CHA2DS2-VASc score, a lower eGFR, higher coronary calcium score
and a larger IMT. Figure 2 shows the correlation between AF burden
and the duration of the longest AF episode [Spearman’s q 0.917 (95%
CI 0.891–0.937), P < 0.001]. Only four patients had long episodes ac-
companied by a low AF burden and two had short episodes with a
high AF burden (Supplementary material online, Figure S1). Examples
of different AF burdens are shown in Supplementary material online,
Figure S2.
Atrial fibrillation progression
In 179 (89%) patients, 1-year rhythm follow-up was available. Figure 3
shows the categorization of patients based on the longest AF episode
duration during the first 6 months as compared to the second
6 months. During follow-up, 111 (62%) patients remained in the
same category, 39 (22%) had progression, and 29 (16%) had regres-
sion. Twenty-nine (74%) out of 39 patients with progression only
progressed to the next category (e.g. short to intermediate or inter-
mediate to long episodes). Eight patients developed persistent AF.
A total of five patients started AAD, three showed AF regression,
and two remained in the same category. Six patients underwent PVI
(three within the first 6 months, three in the second 6 months) three
showed regression, two remained in the same category, and one pa-
tient developed persistent AF and subsequently underwent PVI. On a
quarterly basis, average daily AF burden increased from 3.2% to 3.8%,
5.2%, and 6.1%. When only selecting episodes >1 hours (instead of all
episodes >_2 min) the numbers remained similar: 3.1% to 3.6%, 5.0%,
and 5.9%.
Discussion
In this interim analysis of the RACE V registry, we longitudinally inves-
tigated temporal patterns, burden, and progression of paroxysmal AF
and the association with clinical characteristics using continuous
rhythm monitoring. We found that: (i) paroxysmal self-terminating
AF has very heterogeneous temporal arrhythmia patterns, both in re-
spect to episode duration and AF burden; (ii) patients with longer AF






of AF (N 5 63)
Recurrence
of AF (N 5 139)
P-value (no recurrence
vs. recurrence)
Left ventricular ejection fraction <45% 4 (2%) 2 (3%) 2 (1%) 0.412
Left ventricular mass (g) 162 ± 47 156 ± 45 164 ± 47 0.417
Left ventricular mass index (g/m2) 79 ± 18 77 ± 17 80 ± 19 0.468
Left ventricular hypertrophy 8 (4%) 2 (3%) 6 (4%) 0.700
CT
Calcium score (Agatston) 31 (0–227) 41 (0–262) 26 (0–216) 0.733
Vascular assessment
IMT–CCA (mm) 0.72 (0.63–0.87) 0.71 (0.62–0.88) 0.73 (0.64–0.87) 0.418
IMT–all segments (mm) 0.73 (0.62–0.90) 0.70 (0.60–0.94) 0.74 (0.63–0.87) 0.835
Pulse wave velocity (m/s) 8.3 (7.3–9.7) 8.6 (7.2–9.7) 8.1 (7.3–9.7) 0.382
A P-value is given for the difference between recurrence vs. no recurrence of AF.
Data are presented as mean ± standard deviation, number of patients (%), or median (interquartile range).
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; BMI, body mass index; CT, computed tomography; eGFR estimated glomerular filtration rate; EHRA, European
Heart Rhythm Association class for symptoms; IMT, intima media thickness; NOAC, novel oral anticoagulation; NT-pro BNP, N-terminal pro-brain natriuretic peptide.
aThe number of comorbidities was calculated by awarding points for hypertension, heart failure, age >65 years, diabetes mellitus; coronary artery disease, BMI > 25kg/m2, mod-
erate or severe mitral valve regurgitation and kidney dysfunction (eGFR < 60).
bThe CHA2DS2-VASc score assesses thrombo-embolic risk. C, congestive heart failure/LV dysfunction, H, hypertension; A2, age >_75 years; D, diabetes mellitus; S2, stroke/tran-
sient ischaemic attack/systemic embolism; V, vascular disease; A, age 65–74 years; Sc, sex category (female sex).






/europace/article-abstract/doi/10.1093/europace/euaa123/5869098 by guest on 03 August 2020
comorbidities; and (iii) modest AF progression within 1-year oc-
curred in a substantial number of patients.
Quantifying paroxysmal atrial fibrillation
The currently used clinical AF classification poorly reflects the tem-
poral pattern and burden of AF.79 Patients classified in the same clin-
ical AF category may be inherently heterogeneous in terms of
temporal AF persistence and AF burden. We show that patients ei-
ther had short episodes of AF, or only longer AF episodes with a
strong correlation between duration of the self-terminating AF epi-
sodes and AF burden. In general, in our population AF burden was
low. Only 10 episodes were electrically cardioverted, all other epi-
sodes remained self-terminating during follow-up.
Recently, it was acknowledged that an important knowledge gap
includes understanding the best parameter for AF quantification, as
well as the relation of the amount of AF and stroke and other major
adverse cardiovascular events.10To improve classification for parox-
ysmal AF, Wineinger et al. proposed the ‘staccato’ AF subtype (fre-
quent and short episodes of paroxysmal AF), and the ‘legato’ AF
subtype (infrequent and long episodes of paroxysmal AF), based on
single-lead ECG monitoring for a mean of 11 days in 13 000 patients.8
Unfortunately, no exact cut-off values for this classification were pro-
vided nor were AF patterns correlated to clinical characteristics. In
general, intermittent short-term monitoring precludes optimal classi-
fication of the type of AF. Continuous ECG monitoring can provide
new evidence for the heterogeneity of AF.11 Our study extends these
findings by proposing three patterns of paroxysmal self-terminating
AF based on the duration of the longest episode. Yet, these cut-off
values will need to be validated in future studies.
Comorbidities and atrial fibrillation
The duration of AF episodes may reflect the severity of the atrial car-
diomyopathy which itself relates to the presence of risk factors and
comorbidities next to AF burden.12 Our data support this concept
by showing differences in clinical and echocardiographic characteris-
tics within the three groups of AF episode duration and of AF burden,
with more comorbidities in patients with longer AF episodes and a
higher AF burden. Episode duration might reflect the severity of the
substrate, while the number of shorter AF episodes may be mainly
driven by the amount of triggers. The latter may explain the lack of
association between very short episodes and cardiovascular out-
come.13 Yet, little is known on the exact cut-offs in terms of episode
duration to distinguish both entities.
No recurrence of atrial fibrillation
Despite selecting patients with at least two episodes of AF in the past
year, approximately one third did not show any recurrent AF episode
during the first 6 months of follow-up. The lower left atrial volume in
these patients might indicate less severe structural remodelling. On
the other hand, the number of comorbidities in patients in this group
was similar to that in patients with recurrences. The higher propor-
tion of hypertension and higher CHA2DS2-VASc score in these
patients at baseline together with higher rates of antihypertensive
drugs (ARBs and diuretics) may indicate that comorbidities were
more frequently diagnosed and potentially treated more appropri-
ately. As has been shown by The Routine vs. Aggressive risk factor
driven upstream rhythm Control for prevention of Early atrial fibrilla-
tion in heart failure (RACE 3) trial and The AggRessive Risk factor
Figure 1 Examples of patients with short (A), intermediate (B), and long (C) episodes during 6-month follow-up. Each day is represented by a bar.
White means no AF is present, and blue represents ongoing episodes of AF. AF initiations are shown in red and AF terminations are shown in green.
Shaded areas indicate nightly hours. The Y-axis is the time of day and the X-axis represents 6 months of follow-up. AF, atrial fibrillation.
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Age (years) 63 ± 10 63 ± 10 67 ± 7 0.068
Male sex 17 (38%) 23 (61%) 41 (73%) 0.002
Total history AF (years) 2.1 (0.7–4.5) 1.8 (0.4–3.9) 2.5 (0.6–4.8) 0.384
Heart failure 9 (20%) 16 (42%) 23 (41%) 0.044
Hypertension 20 (44%) 13 (34%) 28 (50%) 0.317
Diabetes 3 (7%) 1 (3%) 7 (13%) 0.205
Coronary artery disease 3 (7%) 3 (8%) 12 (21%) 0.049
Thrombo-embolic events 6 (13%) 3 (8%) 4 (7%) 0.533
Chronic obstructive pulmonary disease 2 (4%) 2 (5%) 4 (7%) 0.836
Number of comorbiditiesa 1.9 ± 1.2 2.0 ± 1.2 2.7 ± 1.4 0.007
CHA2DS2-VASc score
b 1.9 ± 1.1 1.6 ± 1.4 1.9 ± 1.2 0.407
0 4 (9%) 11 (29%) 6 (11%)
1 14 (31%) 10 (26%) 18 (32%)
2 14 (31%) 7 (18%) 14 (25%)
3 10 (22%) 5 (13%) 12 (21%)
4 2 (4%) 4 (11%) 5 (9%)
5 1 (2%) 1 (3%) 1 (2%)
EHRA class 0.965
I 4 (9%) 3 (8%) 6 (11%)
IIa 17 (38%) 17 (45%) 26 (46%)
IIb 22 (49%) 15 (40%) 13 (23%)
III 2 (4%) 3 (8%) 11 (20%)
Height (cm) 173 ± 10 176 ± 11 178 ± 11 0.057
Weight (kg) 82 ± 18 86 ± 16 90 ± 18 0.084
BMI (kg/m2) 27 ± 5 28 ± 4 28 ± 5 0.353
Obesity (BMI > 30) 9 (20%) 8 (21%) 16 (29%) 0.543
Waist circumference (cm) 97 ± 13 101 ± 11 105 ± 13 0.010
Blood pressure (mmHg)
Systolic 135 ± 18 139 ± 20 136 ± 18 0.675
Diastolic 80 ± 10 82 ± 10 81 ± 8 0.616
NT-proBNP (pg/mL) 33 (14–130) 62 (23–165) 48 (22–197) 0.312
Creatinine (mmol/L) 76 (67–85) 80 (71–92) 86 (77–95) 0.009
eGFR (mL/min) 83 (69–90) 79 (66–86) 76 (65–87) 0.297
Medications
b-Blocker 21 (47%) 18 (47%) 32 (57%) 0.501
Verapamil/diltiazem 6 (13%) 9 (24%) 7 (13%) 0.296
Class I antiarrhythmic drugs 17 (38%) 11 (29%) 7 (13%) 0.012
Class III antiarrhythmic drugs 2 (4%) 1 (3%) 5 (9%) 0.393
Digoxin 1 (2%) – 1 (2%) 0.671
ACE-inhibitor 7 (16%) 5 (13%) 13 (23%) 0.403
Angiotensin receptor blocker 5 (11%) 5 (13%) 12 (21%) 0.321
Mineralocorticoid receptor antagonist – 1 (3%) 2 (4%) 0.458
Statin 14 (31%) 8 (21%) 31 (55%) 0.002
Diuretic 4 (9%) 4 (11%) 8 (15%) 0.683
Anticoagulant 0.128
Vitamin K antagonist 5 (9%) 5 (13%) 12 (21%)
NOAC 24 (53%) 18 (47%) 32 (57%)
Echocardiographic variables
Left atrial volume (mL) 71 ± 25 71 ± 23 72 ± 24 0.973
Left atrial volume index (mL/m2) 37 ± 13 37 ± 11 36 ± 11 0.850
Left ventricular ejection fraction (%) 58 (55–60) 58 (55–62) 58 (55–61) 0.573
Continued
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rEduction STudy for Atrial Fibrillation (ARREST-AF), risk factor man-
agement improves sinus rhythm maintenance in patients with AF.14,15
Atrial fibrillation progression
A recent meta-analysis on AF progression showed a pooled inci-
dence of AF progression of 8.1 per 100 patient-years of follow-
up.16This meta-analysis, however, was hampered by differences in
follow-up duration and patient characteristics between the respec-
tive studies, and the use of intermitted rhythm monitoring.
Continuous rhythm monitoring may better define AF progression.11
The relevance of AF progression is that it is associated with worse
clinical outcome. In clinical AF, De Vos et al. showed that progression
from selfterminating to non-selfterminating AF had prognostic clinical
value, which was supported by other studies.1,13 Also in subclinical
AF prolongation of duration of AF episodes from <_24 to >24 hours
was associated with more strokes and more heart failure hospitaliza-
tions.4,17 In a recent high risk elderly population without known AF,
the median AF burden was 0.13% during 40 months of follow-up.
Progression to 24-hour episodes occurred in 33 of 590 patients
(5.6%) indicating that in these high risk patients AF burden was low,
and progression was limited.11 In our cohort with lower risk paroxys-
mal AF patients, we observed a small increase in averaged AF burden
throughout follow-up, and found that 22% of patients showed AF epi-
sode prolongation during 1 year. This indicates that AF progression is
a slow and subtle process. Interestingly, we also found a significant
number of patients with AF regression, which has also been shown
previously.18 Factors such as changes in antiarrhythmic therapy,
which only occurred in a few patients, or more intense risk factor
control may partially explain this interesting observation.14,18
Clinical implications
Continuous rhythm monitoring enables an improved characteriza-
tion of patients with AF. Diverse patterns may reflect differences in
underlying diseases and mechanisms, warranting personalized thera-
peutic interventions and patient tailored therapies. More details on
AF patterns may aid in selecting patients for specific AAD, PVI or
other therapies. Additionally, since AF classification is dynamic, ob-
served longitudinal changes in AF patterns may have clinical utility for
assessing the progression of the underlying substrate as well as moni-
toring response to therapeutic interventions. Clinical implications












Left ventricular ejection fraction < 45% 1 (2%) 1 (3%) – 0.498
Left ventricular mass (g) 141 ± 36 166 ± 36 178 ± 55 0.009
Left ventricular mass index (g/m2) 74 ± 14 78 ± 18 85 ± 21 0.046
Left ventricular hypertrophy 1 (2%) 1 (3%) 4 (7%) 0.402
CT
Calcium score (Agatston) 20 (0–149) 6 (0–143) 58 (1–299) 0.090
Vascular assessment
IMT–CCA (mm) 0.71 (0.62–0.82) 0.72 (0.63–0.89) 0.76 (0.69–0.89) 0.192
IMT–all segments (mm) 0.71 (0.62–0.79) 0.72 (0.62–0.87) 0.77 (0.64–0.94) 0.101
Pulse wave velocity (m/s) 7.9 (7.2–9.8) 7.9 (7.4–10.0) 8.3 (7.4–9.4) 0.976
Data are presented as mean ± standard deviation, number of patients (%), or median (interquartile range).
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; BMI, body mass index; CT, computed tomography; eGFR, estimated glomerular filtration rate; EHRA, European
Heart Rhythm Association class for symptoms; IMT, intima media thickness; NOAC, novel oral anticoagulation; NT-pro BNP, N-terminal pro-brain natriuretic peptide
aThe number of comorbidities was calculated by awarding points for hypertension, heart failure, age >65 years, diabetes mellitus; coronary artery disease, BMI > 25kg/m2, mod-
erate or severe mitral valve regurgitation and kidney dysfunction (eGFR < 60).
bThe CHA2DS2-VASc score assesses thrombo-embolic risk. C, congestive heart failure/LV dysfunction, H, hypertension; A2, age >_75 years; D, diabetes mellitus; S2, stroke/tran-
sient ischaemic attack/systemic embolism; V, vascular disease; A, age 65–74 years; Sc, sex category (female sex).
Figure 2 Scatterplot showing a high rate of agreeability between
the AF burden (X-axis) and the duration of the longest AF episode
(Y-axis), both on logarithmic scales. Data shown for 139 patients
with AF recurrence during 6-month follow-up. In turquoise, four
patients are identified with long AF episodes, with low AF burden.
In green, two patients are identified with short episodes, and high
AF burden. AF, atrial fibrillation; CI, confidence interval.
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Table 3 Patients’ characteristics and AF burden during 6 months
Characteristics Low AF burden
(N 5 50)
Intermediate AF





Age (years) 62 ± 10 64 ± 8 68 ± 8.8 0.005
Male sex 24 (48%) 29 (66%) 28 (62%) 0.173
Total history AF (years) 1.8 (0.6–4.8) 2.9 (0.9–4.6) 1.9 (0.3–4.0) 0.530
Heart failure 13 (26%) 17 (39%) 18 (40%) 0.282
Hypertension 21 (42%) 21 (48%) 19 (42%) 0.824
Diabetes 3 (6%) 1 (2%) 7 (16%) 0.056
Coronary artery disease 3 (6%) 5 (11%) 10 (22%) 0.059
Thrombo-embolic events 5 (10%) 3 (7%) 5 (11%) 0.770
Chronic obstructive pulmonary disease 2 (4%) 3 (7%) 3 (7%) 0.801
Number of comorbiditiesa 1.9 ± 1.2 2.3 ± 1.1 2.2 ± 1.3 0.032
CHA2DS2-VASc score
b 1.6 ± 1.1 1.6 ± 1.3 2.2 ± 1.3 0.019
0 9 (18%) 8 (18%) 4 (9%)
1 14 (28%) 18 (41%) 10 (22%)
2 16 (32%) 8 (18%) 11 (24%)
3 9 (18%) 6 (14%) 12 (27%)
4 2 (4%) 2 (5%) 7 (16%)
5 – 2 (5%) 1 (2%)
EHRA class 0.017
I 3 (6%) 3 (7%) 7 (16%)
IIa 21 (42%) 15 (34%) 24 (53%)
IIb 24 (48%) 18 (41%) 8 (18%)
III 2 (4%) 8 (18%) 6 (13%)
Height (cm) 176 ± 10 177 ± 11 177 ± 11 0.785
Weight (kg) 85 ± 18 90 ± 18 84 ± 17 0.280
BMI (kg/m2) 28 ± 5 29 ± 5 27 ± 5 0.253
Obesity (BMI > 30) 13 (26%) 11 (25%) 9 (20%) 0.768
Waist circumference (cm) 100 ± 14 103 ± 12 102 ± 13 0.486
Blood pressure (mmHg)
Systolic 137 ± 18 139 ± 19 135 ± 19 0.631
Diastolic 82 ± 9 84 ± 10 78 ± 8 0.012
NT-proBNP (pg/mL) 32 (12–127) 46 (22–125) 53 (24–214) 0.101
Creatinine (mmol/L) 79 (68–89) 83 (74–87) 83 (73–100) 0.056
eGFR (mL/min) 85 (71–90) 79 (73–87) 73 (62–86) 0.020
Medications
b-Blocker 25 (50%) 21 (48%) 21 (56%) 0.748
Verapamil/diltiazem 6 (12%) 10 (23%) 6 (13%) 0.312
Class I antiarrhythmic drugs 19 (38%) 11 (25%) 5 (11%) 0.011
Class III antiarrhythmic drugs 1 (2%) 3 (7%) 4 (9%) 0.332
Digoxin – 1 (2%) 1 (2%) 0.565
ACE-inhibitor 8 (16%) 6 (14%) 11 (24%) 0.373
Angiotensin receptor blocker 6 (12%) 7 (16%) 9 (20%) 0.566
Mineralocorticoid receptor antagonist – 1 (2%) 2 (4%) 0.330
Statin 13 (26%) 19 (43%) 21 (47%) 0.083
Diuretic 4 (8%) 7 (16%) 5 (11%) 0.485
Anticoagulant 0.025
Vitamin K antagonist 5 (10%) 7 (16%) 10 (22%)
NOAC 26 (52%) 20 (45%) 28 (62%)
Echocardiographic variables
Left atrial volume (mL) 73 ± 26 71 ± 24 71 ± 22 0.927
Left atrial volume index (mL/m2) 37 ± 12 37 ± 13 37 ± 10 0.989
Left ventricular ejection fraction (%) 58 (55–60) 58 (55–61) 58 (58–61) 0.333
Continued
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Strengths and limitations
Strengths include the well-phenotyped cohort and availability of con-
tinuous rhythm monitoring, for the vast majority in patients without
implanted cardiac devices prior to study enrolment. In contrast, most
other studies with continuous rhythm monitoring were performed in
patients with a pacemaker or defibrillator.1,7,11,17
Limitations include the modest sample size, the limited follow-up
time and the observational nature. At this point it is not yet possible
to show any prognostic value of the different paroxysmal AF entities,
nor were the exact cut-offs for AF episode duration validated.
Inevitably, start and changes of treatment during follow-up will
interfere with the natural course of AF, but are inherent to the nature
of the arrhythmia. To correct for this, sensitivity analyses were per-
formed that showed similar results, although not all differences
remained significant, most likely due to a lack of power. And finally,
we acknowledge the differences in detections of different signals be-
tween the LinQ and pacemaker patients. Nevertheless, AF detection
in Medtronic pacemakers and with the LinQ has been shown to be
very reliable.19,20
Conclusion
Our main findings of this interim analysis include that paroxysmal self-
terminating AF is a very heterogeneous arrhythmia: one third of the
patients did not show any recurrence during 6 months of follow-up.
In those with recurrences, AF patterns varied considerably both with
respect to duration of AF episodes as well as AF burden. Patients
with longer episodes and higher AF burden had more severe underly-
ing comorbidities. Finally, AF progression occurred only in a minority
of patients.
Supplementary material
Supplementary material is available at Europace online.
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Table 3 Continued
Characteristics Low AF burden
(N 5 50)
Intermediate AF





Left ventricular ejection fraction <45% 1 (2%) 1 (2%) – 0.611
Left ventricular mass (g) 152 ± 38 177 ± 52 165 ± 50 0.151
Left ventricular mass index (g/m2) 73 ± 17 84 ± 19 83 ± 20 0.054
Left ventricular hypertrophy 1 (2%) 2 (5%) 3 (7%) 0.533
CT
Calcium score (Agatston) 21 (0–161) 6 (0–96) 94 (16–360) 0.012
Vascular assessment
IMT–CCA (mm) 0.71 (0.61–0.80) 0.74 (0.67–0.91) 0.78 (0.68–0.91) 0.029
IMT–all segments (mm) 0.72 (0.61–0.81) 0.72 (0.62–0.86) 0.78 (0.64–0.95) 0.104
Pulse wave velocity (m/s) 8.0 (7.2–9.9) 8.3 (7.5–9.7) 8.1 (7.3–9.4) 0.903
Data are presented as mean ± standard deviation, number of patients (%), or median (interquartile range).
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; BMI, body mass index; CT, computed tomography; eGFR, estimated glomerular filtration rate; EHRA, European
Heart Rhythm Association class for symptoms; NOAC, novel oral anticoagulation; NT-pro BNP, N-terminal pro-brain natriuretic peptide.
aThe number of comorbidities was calculated by awarding points for hypertension, heart failure, age >65 years, diabetes mellitus; coronary artery disease, BMI > 25kg/m2, mod-
erate or severe mitral valve regurgitation and kidney dysfunction (eGFR < 60).
bThe CHA2DS2-VASc score assesses thrombo-embolic risk. C, congestive heart failure/LV dysfunction, H, hypertension; A2, age >_75 years; D, diabetes mellitus; S2, stroke/tran-
sient ischaemic attack/systemic embolism; V, vascular disease; A, age 65–74 years; Sc, sex category (female sex).
Figure 3 Sankey diagram illustrating the categorization based on
the longest AF episode during the first 6 months on the left, and the
second 6 months on the right. AF, atrial fibrillation.






/europace/article-abstract/doi/10.1093/europace/euaa123/5869098 by guest on 03 August 2020
Conflict of interest: R.G.T. reports grants and personal fees from
Boehringer Ingelheim, personal fees from BMS/Pfizer, personal fees
from Bayer, grants from Medtronic, grants from St Jude Medical, out-
side the submitted work; In addition, R.G.T. has a patent as a co-
inventor of the MyDiagnostick issued. M.E.W.H. reports personal
fees from Medtronic, outside the submitted work. J.R.D.G reports
grants from Abbott, grants and personal fees from Atricure, grants
from Boston Scientific, grants and personal fees from Medtronic,
grants and personal fees from Bayer, personal fees from Daiichi
Sankyo, personal fees from Johnson&Johnson, personal fees from
Novartis, personal fees from Servier, outside the submitted work.
C.O.S.S. and M.d.M. report they are employees of Medtronic. U.S.
reports grants from Dutch Heart Foundation, during the conduct of
the study; personal fees from Johnson & Johnson, grants from
Roche, grants from EP solutions, other from YourRhythmics BV, out-
side the submitted work; In addition, U.S. has a patent Non-invasive
classification of AF issued, and a patent Biomarkers for AF pending.
J.G.L.M.L. reports personal fees from Medtronic, outside the submit-
ted work. H.J.G.M.C. reports Grant to support the present work,
from the Netherlands Cardiovascular Research Initiative: an initiative
with support of the Dutch Heart Foundation, CVON 2014–9:
Reappraisal of Atrial Fibrillation: interaction between
hyperCoagulability, Electrical remodelling, and Vascular destabilisation
in the progression of AF (RACE V). All other authors have nothing
to declare.
References
1. De Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ et al
Progression from paroxysmal to persistent atrial fibrillation clinical correlates
and prognosis. J Am Coll Cardiol 2010;55:725–31.
2. Nattel S, Guasch E, Savelieva I, Cosio FG, Valverde I, Halperin JL et al Early man-
agement of atrial fibrillation to prevent cardiovascular complications. Eur Heart J
2014;35:1448–56.
3. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, et
al; ROCKET-AF Steering Committee and Investigators. Higher risk of death and
stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from
the ROCKET-AF Trial. Eur Heart J 2015;36:288–96.
4. Wong JA, Conen D, Van Gelder IC, McIntyre WF, Crijns HJ, Wang J et al
Progression of device-detected subclinical atrial fibrillation and the risk of heart
failure. J Am Coll Cardiol 2018;71:2603–11.
5. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A
et al Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of
6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:
281–7a.
6. De With RR, Marcos EG, Van Gelder IC, Rienstra M. Atrial fibrillation progres-
sion and outcome in patients with young-onset atrial fibrillation. Europace 2018;
20:1750–7.
7. Charitos EI, Stierle U, Ziegler PD, Baldewig M, Robinson DR, Sievers HH, Hanke
T. A comprehensive evaluation of rhythm monitoring strategies for the detection
of atrial fibrillation recurrence: insights from 647 continuously monitored
patients and implications for monitoring after therapeutic interventions.
Circulation 2012;126:806–14.
8. Wineinger NE, Barrett PM, Zhang Y, Irfanullah I, Muse ED, Steinhubl SR et al
Identification of paroxysmal atrial fibrillation subtypes in over 13,000 individuals.
Heart Rhythm 2019;16:26–30.
9. De With RR, Marcos EG, Dudink E, Spronk HM, Crijns H, Rienstra M et al Atrial
fibrillation progression risk factors and associated cardiovascular outcome in
well-phenotyped patients: data from the AF-RISK study. Europace 2020;22:
352–60.
10. Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, et al;
American Heart Association Council on Clinical Cardiology, Council on
Cardiovascular and Stroke Nursing, Council on Quality of Care and Outcomes
Research, and Stroke Council. Atrial fibrillation burden: moving beyond atrial fi-
brillation as a binary entity: a scientific statement from the American Heart
Association. Circulation 2018;137:e623–e644.
11. Diederichsen SZ, Haugan KJ, Brandes A, Lanng MB, Graff C, Krieger D et al
Natural history of subclinical atrial fibrillation detected by implanted loop
recorders. J Am Coll Cardiol 2019;74:2771–81.
12. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA et al Document
Reviewers. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomy-
opathies: definition, characterization, and clinical implication. Europace 2016;18:
1455–90.
13. Steinberg BA, Piccini JP. When low-risk atrial fibrillation is not so low risk: beast
of burden. JAMA Cardiol 2018;3:558–60.
14. Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brugemann J,
Geelhoed B, Tieleman RG, Hillege HL, Tukkie R, Van Veldhuisen DJ, Crijns H,
Van Gelder IC; RACE 3 Investigators. Targeted therapy of underlying conditions
improves sinus rhythm maintenance in patients with persistent atrial fibrillation:
results of the RACE 3 trial. Eur Heart J 2018;39:2987–96.
15. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX et al
Long-term effect of goal-directed weight management in an atrial fibrillation co-
hort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 2015;65:2159–69.
16. Blum S, Meyre P, Aeschbacher S, Berger S, Auberson C, Briel M et al Incidence
and predictors of atrial fibrillation progression: a systematic review and meta-
analysis. Heart Rhythm 2019;16:502–10.
17. Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MR et al
Duration of device-detected subclinical atrial fibrillation and occurrence of
stroke in ASSERT. Eur Heart J 2017;38:1339–44.
18. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R et al
PREVEntion and regReSsive Effect of weight-loss and risk factor modification on
Atrial Fibrillation: the REVERSE-AF study. Europace 2018;20:1929–35.
19. Sanders P, Purerfellner H, Pokushalov E, Sarkar S, Di Bacco M, Maus B et al;
Reveal LINQ Usability Investigators. Performance of a new atrial fibrillation de-
tection algorithm in a miniaturized insertable cardiac monitor: results from the
Reveal LINQ Usability Study. Heart Rhythm 2016;13:1425–30.
20. Passman RS, Weinberg KM, Freher M, Denes P, Schaechter A, Goldberger JJ et al
Accuracy of mode switch algorithms for detection of atrial tachyarrhythmias.
J Cardiovasc Electrophysiol 2004;15:773–7.






/europace/article-abstract/doi/10.1093/europace/euaa123/5869098 by guest on 03 August 2020
